Rhumbline Advisers Cyclerion Therapeutics, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$2.18 - $4.29 $74,479 - $146,567	-34,165 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$2.69 - $5.12 $269 - $512	100 Added 0.29%	34,165 $95,000
Q4 2020 Feb 10, 2021	BUY	$2.25 - $7.12 $10,467 - $33,122	4,652 Added 15.82%	34,065 $104,000
Q3 2020 Nov 12, 2020	SELL	$3.46 - $8.39 $16,213 - $39,315	-4,686 Reduced 13.74%	29,413 $179,000
Q2 2020 Aug 13, 2020	BUY	$2.37 - $7.14 $18,393 - $55,413	7,761 Added 29.47%	34,099 $202,000
Q4 2019 Feb 05, 2020	BUY	$1.8 - $13.43 $558 - $4,163	310 Added 1.19%	26,338 $72,000
Q3 2019 Oct 23, 2019	BUY	$8.12 - $14.54 $2,444 - $4,376	301 Added 1.17%	26,028 $315,000
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $246,979 - $587,861	25,727 New	25,727 $295,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $112M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.